102
Cordlife Group Limited
Annual Report 2016
Notes to
The Financial Statements
for the financial year ended 30 June 2016
34. Investment in subsidiaries (cont’d)
Name of company
Country of
incorporation
Principal activities
Percentage of
equity held
2016
2015
%
%
Held by the Company:
Cordlife (Hong Kong) Limited
1
Hong Kong
Cord blood and cord
100
100
lining banking services
Cordlife Technologies Pte. Ltd.
2
Singapore
Cord lining banking
100
100
services
Shanghai Cordlife Biomedical
People’s
Dormant
100
100
Research Co., Ltd
3
Republic of
China
CS Cell Technologies Pte. Ltd.
2
Singapore
Investment holding
100
100
Cordlife Stem Cell Technology Limited
1
Hong Kong
Cord lining banking
100
100
services
Stemlife Berhad
6
Malaysia
Cord blood and cord
89.88
31.81
lining banking services
Held by CS Cell Technologies Pte Ltd
Cordlife Sciences (India) Pvt. Ltd.
4
India
Cord blood and cord
99.99
85
lining banking services
Cordlife Medical Phils., Inc
5
Philippines
Cord blood and cord
99.99
99.99
lining banking services
PT. Cordlife Persada
7
Indonesia
Cord blood and cord
67
67
lining banking services
Held by Cordlife Stem Cell Technology
Limited
Hong Kong Screening Centre Limited
1
Hong Kong
Newborn screening for
67
67
metabolic disorders
1
Audited by Ernst & Young, Hong Kong
2
Audited by Ernst & Young LLP, Singapore
3
Audited by Shanghai Xinyi Certified Public Accountants Co. Ltd
4
Audited by D.N Mukherjee & Co.
5
Audited by Datiles Casedo and Associates, CPAs
6
Audited by Ernst & Young, Kuala Lumpur
7
Not required for statutory audit
8
As at 30 June 2015, the investment in Stemlife Berhad was classified as an associate (Note 11)
